Visit us at D8 and discover how our regenerative solutions.

Let’s connect at our booth to discuss how Regen Lab is transforming healthcare with innovative, science-driven solutions.

Don’t miss this opportunity to network and learn at one of the premier global congresses in wound care

EWMA 2026 Symposium

Case reports: initial feedback on an autologous innovation in the treatment of chronic wounds

 

At EWMA 2026, Regen Lab is pleased to invite healthcare professionals to a dedicated symposium focused on innovation in wound care.

This scientific session will present clinical case reports, early feedback from practice, and initial perspectives on an autologous innovation developed to support new approaches in wound care.

Chaired by Mr Gerald Hofer, the symposium will feature presentations from:

Dr Maria Andreea Nagy | Germany
Dr Hester Colboc | France

Through these lectures, attendees will gain insight into:

  • early clinical experience with RegenWound-HA Set
  • practical case-based observations
  • and the opportunities this innovation may offer in the treatment of chronic wounds.

Date: Thursday 7 May 2026

Join us for this important scientific exchange and discover how autologous innovation may help shape the future of chronic wound management.

RegenWound-HA Set

MEDICAL PURPOSE

Set for the safe preparation of autologous RegenPRP™ and subsequent wound dressing

COMPOSITION

  1. Cellular Membrane CM-HA tube
  2. Silicone Wound Contact Layer
  3. Surgical bowl
  4. 5ml syringe Luer-Lock
  5. Safety-Lok Blood Collection Set with Pre-Attached Holder
  6. Blood Transfer Device

About Us

Since 2003, Regen Lab SA has specialized in designing and manufacturing high-quality medical devices for cell therapies and the preparation of autologous platelet-rich plasma (PRP) from the patient's own blood for bedside procedures.

More

Milestones

2003 - Foundation
2010 - RegenKit first approval in bone graft
2013 - A new state-of-theart laboratory in Lausanne
2014 - Cellular Matrix first approval
2015 - Launch of Cellular Matrix in Europe

More

Vision

Founded in 2003, Regen Lab has become a global reference thanks to its commitment to innovation, quality, and the effectiveness of its therapeutic solutions. Here’s how we have transformed the medical landscape over the past two decades.

More

RegenPRP™

RegenPRP™ is a medical treatment that uses platelet-rich plasma from the patient's own blood to enhance and tissue regeneration.

More

RegenPRP™ - HA

RegenPRP™ - HA combination is an innovative treatment combining platelet-rich plasma (PRP) and hyaluronic acid to improve tissue regeneration and healing.

More

RegenPRP™ - ATS

RegenPRP™ combined with ATS (Autologous Thrombin Serum) is an advanced approach to tissue regeneration that uses autologous thrombin-enriched platelet-rich plasma (PRP) to maximise healing effects.

More

RegenExtracell®

RegenExtracell is an innovative tissue regeneration treatment using an extracellular matrix enriched with platelet-rich plasma (PRP).

More

Hyaluronic Acid

Coming Soon

Regulatory

Manufacturers of medical devices based outside the EU must designate an Authorized Representative (EU-REP) established within the EU in order to meet the CE requirements for placing medical devices on the EU market.

More

Quality Management

Regen Lab Quality System Management ensures the consistency of our products quality in total GMP compliance.

Our production facility rooms atmosphere is monitored to satisfy non-pyrogenic medical devices manufacturing.

More

Patents

As a leader in the PRP&HA regenerative field and as an innovation-driven company, Regen Lab SA has devoted important resources since 2004 to put on the market pioneering and diversified products constituting a complete set of tools/technologies for the medical community.

More